| pubmed-article:1396873 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1396873 | lifeskim:mentions | umls-concept:C1522564 | lld:lifeskim |
| pubmed-article:1396873 | lifeskim:mentions | umls-concept:C1511790 | lld:lifeskim |
| pubmed-article:1396873 | lifeskim:mentions | umls-concept:C0034606 | lld:lifeskim |
| pubmed-article:1396873 | lifeskim:mentions | umls-concept:C0205210 | lld:lifeskim |
| pubmed-article:1396873 | lifeskim:mentions | umls-concept:C0303322 | lld:lifeskim |
| pubmed-article:1396873 | pubmed:issue | 9 | lld:pubmed |
| pubmed-article:1396873 | pubmed:dateCreated | 1992-10-28 | lld:pubmed |
| pubmed-article:1396873 | pubmed:abstractText | In a clinical study, the value of thallium-201 reinjection was studied in 139 patients with suspected or known coronary artery disease who showed one or more persistent defects after conventional stress-redistribution imaging. Fifty-nine (42%) patients had sustained a Q-wave myocardial infarction. Sixty-eight (49%) patients showed a reversible defect in at least one myocardial segment at redistribution, while 71 (51%) had persistent defects only. Following reinjection additional segmental filling-in was seen in 95 (68%) patients, including 50 of the 68 (74%) patients with reversible defects and 45 of the 71 (63%) with persistent defects only. On the immediately post-exercise images, 458 (47%) of 973 segments showed perfusion defects. At redistribution 105 (23%) of the 458 defects showed filling-in, whereas of the remaining 353 persistent defects 164 (46%) resolved additionally after reinjection. Thirteen (10%) of 133 Q-wave related defects showed filling-in at redistribution compared with 22 (27%) of 82 remote defects (P = 0.001). After reinjection additional filling-in of defects was seen in 47 (39%) of 120 Q-wave related defects compared with 35 (58%) or 60 remote defects (P = 0.015). Overall, 60 (45%) of 133 Q-wave related defects resolved compared with 57 (70%) of 82 remote defects (P = 0.005).(ABSTRACT TRUNCATED AT 250 WORDS) | lld:pubmed |
| pubmed-article:1396873 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1396873 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1396873 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1396873 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1396873 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1396873 | pubmed:issn | 0340-6997 | lld:pubmed |
| pubmed-article:1396873 | pubmed:author | pubmed-author:PauwelsE KEK | lld:pubmed |
| pubmed-article:1396873 | pubmed:author | pubmed-author:van der... | lld:pubmed |
| pubmed-article:1396873 | pubmed:author | pubmed-author:ZwindermanA... | lld:pubmed |
| pubmed-article:1396873 | pubmed:author | pubmed-author:NiemeyerM GMG | lld:pubmed |
| pubmed-article:1396873 | pubmed:author | pubmed-author:OosterhuisW... | lld:pubmed |
| pubmed-article:1396873 | pubmed:author | pubmed-author:VliegenH WHW | lld:pubmed |
| pubmed-article:1396873 | pubmed:author | pubmed-author:KuijperA FAF | lld:pubmed |
| pubmed-article:1396873 | pubmed:author | pubmed-author:van... | lld:pubmed |
| pubmed-article:1396873 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1396873 | pubmed:volume | 19 | lld:pubmed |
| pubmed-article:1396873 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1396873 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1396873 | pubmed:pagination | 783-9 | lld:pubmed |
| pubmed-article:1396873 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:1396873 | pubmed:meshHeading | pubmed-meshheading:1396873-... | lld:pubmed |
| pubmed-article:1396873 | pubmed:meshHeading | pubmed-meshheading:1396873-... | lld:pubmed |
| pubmed-article:1396873 | pubmed:meshHeading | pubmed-meshheading:1396873-... | lld:pubmed |
| pubmed-article:1396873 | pubmed:meshHeading | pubmed-meshheading:1396873-... | lld:pubmed |
| pubmed-article:1396873 | pubmed:meshHeading | pubmed-meshheading:1396873-... | lld:pubmed |
| pubmed-article:1396873 | pubmed:meshHeading | pubmed-meshheading:1396873-... | lld:pubmed |
| pubmed-article:1396873 | pubmed:meshHeading | pubmed-meshheading:1396873-... | lld:pubmed |
| pubmed-article:1396873 | pubmed:meshHeading | pubmed-meshheading:1396873-... | lld:pubmed |
| pubmed-article:1396873 | pubmed:meshHeading | pubmed-meshheading:1396873-... | lld:pubmed |
| pubmed-article:1396873 | pubmed:meshHeading | pubmed-meshheading:1396873-... | lld:pubmed |
| pubmed-article:1396873 | pubmed:meshHeading | pubmed-meshheading:1396873-... | lld:pubmed |
| pubmed-article:1396873 | pubmed:year | 1992 | lld:pubmed |
| pubmed-article:1396873 | pubmed:articleTitle | The clinical impact of thallium-201 reinjection scintigraphy for detection of myocardial viability. | lld:pubmed |
| pubmed-article:1396873 | pubmed:affiliation | Department of Diagnostic Radiology (Division of Nuclear Medicine), University of Leiden, Netherlands. | lld:pubmed |
| pubmed-article:1396873 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1396873 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1396873 | lld:pubmed |
